- News Releases
-
- Jan. 13, 2022 (PDF/173KB)R&D
- Kitasato Institute and Sumitomo Dainippon Pharma Start Phase 1 Study on New Drug Candidate Compound Discovered in Joint Research as Treatment for Carbapenem-resistant Bacterial Infections
-
- Dec. 15, 2021 (PDF/119KB)R&D
- Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888 in Patients with Glioblastoma Terminates
-
- Dec. 09, 2021 (PDF/103KB)Corporate
- Notice of the Decision of USPTO on Inter Partes Review (IPR) Proceeding for Method of Use Patent of LATUDA
-
- Dec. 08, 2021 (PDF/2,718KB)CSR
- ESG Meeting (Discussion with Investors)
Other Notices
-
- Dec. 06, 2021Others
- Posted Integrated Report 2021
-
- Nov. 30, 2021Others
- Posted Factbook 2021 ver.2
-
- Nov. 12, 2021CSR (PDF/141KB)
- Sumitomo Dainippon Pharma Receives the Gold Rating in the PRIDE Index for Initiatives Related to LGBTQ for the Second Consecutive Year
IR Library
-
Change company name from April 2022
-
Continuing to challenge ourselves to support a healthy future for people
-
Aiming to create innovative pharmaceutical products
-
Targeting sustainable growth
-
Thinking BEYOND medication